Latest Soleus Capital Management, L.P. Stock Portfolio

Soleus Capital Management, L.P. Performance:

2025 Q3: 13.2%YTD: -3.26%2024: 2.36%

Performance for 2025 Q3 is 13.2%, and YTD is -3.26%, and 2024 is 2.36%.

About Soleus Capital Management, L.P. and 13F Hedge Fund Stock Holdings

In it's latest 13F Holdings report, Soleus Capital Management, L.P. reported an equity portfolio of $2 Billions as of 30 Sep, 2025.

The top stock holdings of Soleus Capital Management, L.P. are KRYS, TGTX, NVCR. The fund has invested 9.1% of it's portfolio in KRYSTAL BIOTECH INC and 7% of portfolio in TG THERAPEUTICS INC .

The fund managers got completely rid off UNITEDHEALTH GROUP INC (UNH), SURMODICS INC (SRDX) and HUMANA INC (HUM) stocks. They significantly reduced their stock positions in INSMED INC (INSM), TREVI THERAPEUTICS INC (TRVI) and ALNYLAM PHARMACEUTICALS INC (ALNY). Soleus Capital Management, L.P. opened new stock positions in AMICUS THERAPEUTICS INC (FOLD), INDIVIOR PLC and NEUROCRINE BIOSCIENCES INC (NBIX). The fund showed a lot of confidence in some stocks as they added substantially to VERICEL CORP (VCEL), MADRIGAL PHARMACEUTICALS INC (MDGL) and CERIBELL INC.

Soleus Capital Management, L.P. Annual Return Estimates Vs S&P 500

Our best estimate is that Soleus Capital Management, L.P. made a return of 13.2% in the last quarter. In trailing 12 months, it's portfolio return was -8.27%.

Performance
S&P 500

New Buys

Ticker	$ Bought
amicus therapeutics inc	36,957,200
indivior plc	35,345,300
neurocrine biosciences inc	19,372,400
belite bio inc	15,540,000
rapt therapeutics inc	13,872,500
uniqure nv	11,674,000
globus med inc	10,079,500
gsk plc	9,495,200

New stocks bought by Soleus Capital Management, L.P.

Additions

Ticker	% Inc.
vericel corp	877
madrigal pharmaceuticals inc	754
ceribell inc	620
ani pharmaceuticals inc	570
inspire med sys inc	568
twist bioscience corp	426
adma biologics inc	321
elevance health inc formerly	270

Additions to existing portfolio by Soleus Capital Management, L.P.

Reductions

Ticker	% Reduced
insmed inc	-96.5
trevi therapeutics inc	-96.43
alnylam pharmaceuticals inc	-85.71
staar surgical co	-83.25
immunic inc	-78.34
septerna inc	-75.8
iovance biotherapeutics inc	-70.06
urogen pharma ltd	-68.92

Soleus Capital Management, L.P. reduced stake in above stock

Sold off

Ticker	$ Sold
theratechnologies inc	-11,331,200
mural oncology pub ltd co	-3,269,980
cytomx therapeutics inc	-2,960,760
the beauty health company	-1,910,000
surmodics inc	-23,443,000
y-mabs therapeutics inc	-1,578,420
enovis corporation	-9,878,400
orthofix med inc	-2,911,790

Soleus Capital Management, L.P. got rid off the above stocks

Sector Distribution

Soleus Capital Management, L.P. has about 83.7% of it's holdings in Healthcare sector.

Sector	%
Healthcare	83.7
Others	16.3

Market Cap. Distribution

Soleus Capital Management, L.P. has about 11.8% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
MID-CAP	38
SMALL-CAP	26.3
UNALLOCATED	16.3
LARGE-CAP	11.8
MICRO-CAP	6.7

Stocks belong to which Index?

About 54.4% of the stocks held by Soleus Capital Management, L.P. either belong to S&P 500 or RUSSELL 2000 index.

Index	%
RUSSELL 2000	49.9
Others	45.6
S&P 500	4.5

Top 5 Winners (%)		%
CELC	celcuity inc	187.9 %
VSTM	verastem inc	112.8 %
ADVM	adverum biotechnologies inc	110.7 %
TERN	terns pharmaceuticals inc	101.1 %
CDTX	cidara therapeutics inc	90.8 %

Top 5 Winners ($)		$
CELC	celcuity inc	75.5 M
KRYS	krystal biotech inc	37.9 M
TERN	terns pharmaceuticals inc	30.8 M
UTHR	united therapeutics corp del	23.7 M
CDTX	cidara therapeutics inc	22.5 M

Top 5 Losers (%)		%
EPIX	essa pharma inc	-85.7 %
MYO	myomo inc	-58.7 %
JSPR	jasper therapeutics inc	-57.1 %
INSP	inspire med sys inc	-30.1 %
EOLS	evolus inc	-28.1 %

Top 5 Losers ($)		$
NVCR	novocure ltd	-40.4 M
INSP	inspire med sys inc	-23.3 M
ELV	elevance health inc formerly	-10.9 M
TWST	twist bioscience corp	-9.6 M
EOLS	evolus inc	-5.5 M

Soleus Capital Management, L.P. Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Soleus Capital Management, L.P.

Soleus Capital Management, L.P. has 87 stocks in it's portfolio. About 44.9% of the portfolio is in top 10 stocks. NVCR proved to be the most loss making stock for the portfolio. CELC was the most profitable stock for Soleus Capital Management, L.P. last quarter.

Last Reported on: 14 Nov, 2025

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
ACLX	arcellx inc	0.41	100,000	8,210,000	reduced	-18.72

ADMA	adma biologics inc	0.54	738,000	10,819,100	added	321

ADPT	adaptive biotechnologies cor	0.00	0.00	0.00	sold off	-100

ADVM	adverum biotechnologies inc	0.07	287,246	1,301,220	unchanged	0.00

AKRO	akero therapeutics inc	0.17	71,000	3,371,080	reduced	-1.39

ALNY	alnylam pharmaceuticals inc	0.35	15,250	6,954,000	reduced	-85.71

ANAB	anaptysbio inc	0.96	626,040	19,169,300	added	95.00

ANIP	ani pharmaceuticals inc	1.57	340,243	31,166,300	added	570

AVTE	jade biosciences inc	0.35	796,744	6,875,900	unchanged	0.00

AXGN	axogen inc	1.55	1,726,550	30,801,700	added	18.31

AXSM	axsome therapeutics inc	0.00	0.00	0.00	sold off	-100

BCYC	bicycle therapeutics plc	0.00	0.00	0.00	sold off	-100

BMRN	biomarin pharmaceutical inc	2.43	890,304	48,218,900	reduced	-1.33

CCCC	c4 therapeutics inc	0.79	7,053,940	15,659,800	added	1.07

CDTX	cidara therapeutics inc	2.38	493,811	47,287,300	added	6.7

CELC	celcuity inc	2.93	1,178,860	58,235,700	reduced	-60.86

CTMX	cytomx therapeutics inc	0.00	0.00	0.00	sold off	-100

DCTH	delcath sys inc	0.00	10,000	107,500	reduced	-60.00

DNLI	denali therapeutics inc	0.00	0.00	0.00	sold off	-100

ELV	elevance health inc formerly	4.22	259,650	83,898,100	added	270